Pharmaceutical Shares of Denmark’s Lundbeck were up more than 9% this morning, after the CNS specialist released its 2022 financial results, showing that growth of its strategic brands accelerated further with an increase of 31% (+20% in local currencies) in 2022, reaching 12.1 billion kroner ($1.76 billion), and representing 67% of overall revenue. 7 February 2023